EAACI Congress 2024

Back
31 May - 03 June 2024 Valencia, Spain

Efficacy and safety of switching to bilastine, a histamine H1 receptor antagonist, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a phase IV, multicenter, open-label, randomized, parallel-group comparative controlled trial

Saturday 01 Jun, 13:15 PM - 13:22 PM Valencia, Spain